MAF is an inclusion criterion in 27 clinical trials for multiple myeloma, of which 18 are open and 9 are closed. Of the trials that contain MAF status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), and 14 are phase 2 (9 open) [4].

MAF is an inclusion criterion in 11 clinical trials for plasma cell leukemia, of which 6 are open and 5 are closed. Of the trials that contain MAF status and plasma cell leukemia as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 8 are phase 2 (5 open) [4].

MAF is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain MAF status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (1 open) [4].

MAF is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain MAF status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

MAF is an inclusion criterion in 3 clinical trials for chronic myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain MAF status and chronic myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

MAF is an inclusion criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain MAF status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

MAF is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MAF status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open) [4].

MAF is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MAF status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MAF is an inclusion criterion in 2 clinical trials for chronic myelomonocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MAF status and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

MAF is an inclusion criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MAF status and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [4].

MAF is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MAF status and lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MAF status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAF status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains MAF status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [4].

MAF is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAF status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for plasmacytoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and plasmacytoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAF status and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for small lymphocytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MAF status and small lymphocytic lymphoma as inclusion criteria, 1 is phase 2 (0 open) [4].

MAF is an inclusion criterion in 1 clinical trial for smoldering plasma cell myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and smoldering plasma cell myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MAF status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

MAF is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAF status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MAF status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAF is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 0 are open and 1 is closed. Of the trial that contains MAF status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (0 open) [4].